Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.97 |
| ▸ | NPC1 | O15118 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL5741903 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL6701905 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL29406979 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL29895228 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL23230 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL3866334 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL7327367 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL1560715 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL33371 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL4620487 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548606-B1 | IN VITRO GASTROINTESTINAL MODEL COMPRISING LAMINA PROPRIA-DERIVED CELLS | EMULATE INC (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3954757-A1 | IN VITRO GASTROINTESTINAL MODEL COMPRISING LAMINA PROPRIA-DERIVED CELLS | Emulate, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11230688-B2 | In vitro gastrointestinal model comprising lamina propria-derived cells | EMULATE, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11001795-B2 | In vitro gastrointestinal model comprising lamina propria-derived cells | EMULATE, Inc. (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3548606-A1 | IN VITRO GASTROINTESTINAL MODEL COMPRISING LAMINA PROPRIA-DERIVED CELLS | Emulate, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10245224-B2 | Topically applied cosmetic reductive composition containing keratin and sulphur | PATRICIO ALFREDO RODRIGUEZ CERDA (CL) | 2019-04-02 | — | — | US | disclosed |
| US-20180224432-A1 | IN VITRO GASTROINTESTINAL MODEL COMPRISING LAMINA PROPRIA-DERIVED CELLS | EMULATE, Inc. | 2018-08-09 | — | — | US | disclosed |
| WO-2018102202-A1 | IN VITRO GASTROINTESTINAL MODEL COMPRISING LAMINA PROPRIA-DERIVED CELLS | EMULATE, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180147130-A1 | Topically Applied Cosmetic Reductive Composition Containing Keratin And Sulphur | RODRIGUEZ CERDA, Patricio Alfredo (CL) | 2018-05-31 | — | — | US | disclosed |
| EP-3191105-A1 | SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF | Braintree Laboratories, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040733-A1 | SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF | BRAINTREE LABORATORIES, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1463711-A4 | A NOVEL POLYMORPH OF SERTRALINE HYDROCHLORIDE AND COMPOSITION CONTAINING THEREOF, NOVEL METHODS FOR PREPARATION OF SERTRALINE HYDROCHLORIDE POLYMORPHS AND AMORPHOUS FORM | TEVA PHARMA (IL) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1463711-A1 | A NOVEL POLYMORPH OF SERTRALINE HYDROCHLORIDE AND COMPOSITION CONTAINING THEREOF, NOVEL METHODS FOR PREPARATION OF SERTRALINE HYDROCHLORIDE POLYMORPHS AND AMORPHOUS FORM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003051818-A1 | A NOVEL POLYMORPH OF SERTRALINE HYDROCHLORIDE AND COMPOSITION CONTAINING THEREOF, NOVEL METHODS FOR PREPARATION OF SERTRALINE HYDROCHLORIDE POLYMORPHS AND AMORPHOUS FORM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-06-26 | — | — | WO | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |